NuVasive Announces Preliminary Unaudited Full Year 2007 Financi...( Anticipates Full Year 2007 Reve...),Health

Anticipates Full Year 2007 Revenue of Approximately $154 million Announces Full Year 2008 Revenue Guidance of $204 Million to $208 Million

and Reiterates Marginal GAAP Profitability

SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced preliminary unaudited financial results for the full year ended December 31, 2007 and provided financial guidance for the full year 2008.

NuVasive anticipates full year 2007 revenue of approximately $154 million. The Company announced anticipated full year 2007 revenue in advance of its National Sales Meeting, which will take place January 25-26, 2008. NuVasive's previously announced guidance for 2007 non-GAAP earnings remains unchanged.

NuVasive also announced revenue guidance for the full year 2008. The Company expects full year 2008 revenue to be in the range of $204 million to $208 million and reiterated its previous guidance of marginal GAAP profitability.

NuVasive will not be holding a conference call to discuss its preliminary unaudited full year 2007 financial results. The Company will announce complete financial and operating details of its fourth quarter and full year ended December 31, 2007 after the market closes on February 19, 2008 and hold a conference call at 5:30 p.m. ET (2:30 p.m. PT).

Alex Lukianov, Chairman and Chief Executive Officer, said, "We are very pleased with the Company's performance in 2007 and look forward to recognizing and rewarding our top performers at this week's National Sales Meeting. We remain on track to meet our long-term goal of mid-30% revenue growth rate over the next several years."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product p
'/>"/>